Ausgabe 4/2015
Inhalt (25 Artikel)
Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer
Edgardo Rivera, Mary Cianfrocca
Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere
John L. Pilon, Dane J. Clausen, Ryan J. Hansen, Paul J. Lunghofer, Brad Charles, Barbara J. Rose, Douglas H. Thamm, Daniel L. Gustafson, James E. Bradner, Robert M. Williams
Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study
Roberto Petrioli, Giandomenico Roviello, Anna Ida Fiaschi, Letizia Laera, Daniele Marrelli, Franco Roviello, Edoardo Francini
Biological evaluation of 4,5-diarylimidazoles with hydroxamic acid appendages as novel dual mode anticancer agents
Katharina Mahal, Sebastian Schruefer, Gustav Steinemann, Franziska Rausch, Rainer Schobert, Bernhard Biersack, Michael Höpfner
Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease
Emily Chan, Eunice L. Kwak, Jimmy Hwang, Marja Heiskala, Guillaume de La Bourdonnaye, Monica Mita
Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer
Hyeong Su Kim, Ho Young Kim, Dae Young Zang, Ho Suk Oh, Jang Yong Jeon, Ji Woong Cho, Choong Kee Park, Jong Hyeok Kim, Min-Jeong Kim, Hong Il Ha, Jung Han Kim, Boram Han, Hunho Song, Jung Hye Kwon, Dae Ro Choi, Joo Young Jung
Stabilization of the Karenitecin ® lactone by alpha-1 acid glycoprotein
Shijie Yao, Pavankumar Petluru, Aulma Parker, Daoyuan Ding, Xinghai Chen, Qiuli Huang, Harry Kochat, Frederick Hausheer
A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258)
Jeffrey R. Infante, Ramesh K. Ramanathan, Daniel George, Eugene Tan, Michelle Quinlan, Angela Liu, Jeffrey W. Scott, Sunil Sharma
A randomized study of cisplatin and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma
Myeong Jun Song, Si Hyun Bae, Ho Jong Chun, Jong Young Choi, Seung Kew Yoon, Jun Young Park, Kwang Hyub Han, Young Seok Kim, Hyung Joon Yim, Soon Ho Um, Woo Jin Chung, Jae Seok Hwang, Sung-Bum Cho, Jong Ryul Eun
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors
David M. Hyman, Alexandra E. Snyder, Richard D. Carvajal, John F. Gerecitano, Martin H. Voss, Alan L. Ho, Jason Konner, Jennifer L. Winkelmann, Megan A. Stasi, Kelsey R. Monson, Alexia Iasonos, David R. Spriggs, Philip Bialer, Mario E. Lacouture, Jerrold B. Teitcher, Nora Katabi, Matthew G. Fury
Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer
In Gyu Hwang, Joung-Soon Jang, Sung Yong Oh, Myung Hwan Rho, Suee Lee, Young Suk Park, Joon Oh Park, Eun Mi Nam, Hyo Rak Lee, Hyun Jung Jun, Kyong-Choun Chi
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy
M. Joerger, A. D. R. Huitema, H. Boot, A. Cats, V. D. Doodeman, P. H. M. Smits, L. Vainchtein, H. Rosing, I. Meijerman, M. Zueger, D. Meulendijks, T. D. Cerny, J. H. Beijnen, J. H. M. Schellens
Synthesis and biological evaluation of geldanamycin analogs against human cancer cells
Yan-ping Li, Jin-jing Chen, Jia-jia Shen, Jing Cui, Lin-zhuan Wu, Zhen Wang, Zhuo-rong Li
Hepatitis B virus reactivation and hepatitis in gastrointestinal cancer patients after chemotherapy
Yu Yang, Yang Du, Wu-Xia Luo, Cong Li, Ye Chen, Ke Cheng, Jing Ding, Yi Zhou, Jun Ge, Xian Yang, Ji-Yan Liu
A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients
Eirini Panoilia, Emilie Schindler, Epaminontas Samantas, Gerasimos Aravantinos, Haralabos P. Kalofonos, Christos Christodoulou, George P. Patrinos, Lena E. Friberg, Gregory Sivolapenko
Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer
Hirotoshi Ishiwatari, Tsuyoshi Hayashi, Makoto Yoshida, Michihiro Ono, Tsutomu Sato, Koji Miyanishi, Yasushi Sato, Rishu Takimoto, Masayoshi Kobune, Junji Kato
Serum metallothionein in patients with testicular cancer
Blanka Tariba, Tanja Živković, Nesrete Krasnići, Vlatka Filipović Marijić, Marijana Erk, Marija Gamulin, Mislav Grgić, Alica Pizent
Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)
P. Katsaounis, A. Kotsakis, S. Agelaki, E. Kontopodis, A. Agelidou, N. Kentepozidis, L. Vamvakas, A. Christopoulou, N. Karachaliou, D. Hatzidaki, V. Georgoulias
Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy
Kenta Nio, Shuji Arita, Taichi Isobe, Hitoshi Kusaba, Kenichi Kohashi, Tatsuhiro Kajitani, Shingo Tamura, Gen Hirano, Kenji Mitsugi, Akitaka Makiyama, Taito Esaki, Hiroshi Ariyama, Yoshinao Oda, Koichi Akashi, Eishi Baba
Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody
Georgina Meneses-Lorente, Thomas Friess, Irene Kolm, Gabriele Hölzlwimmer, Sabine Bader, Christophe Meille, Marlene Thomas, Birgit Bossenmaier
Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study
Herbert I. Hurwitz, David C. Smith, Henry C. Pitot, Jeffrey M. Brill, Rashmi Chugh, Elisabeth Rouits, Joseph Rubin, John Strickler, Gregoire Vuagniaux, J. Mel Sorensen, Claudio Zanna
Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer
Yu-Wen He, Mei-Ling Zhao, Xin-Yun Yang, Jun Zeng, Qiu-Hua Deng, Jian-Xing He
Phase I trial of valproic acid and lenalidomide in patients with advanced cancer
Mehmet Asim Bilen, Siqing Fu, Gerald S. Falchook, Chaan S. Ng, Jennifer J. Wheler, Maen Abdelrahim, Basak Erguvan-Dogan, David S. Hong, Apostolia M. Tsimberidou, Razelle Kurzrock, Aung Naing
Response to: comment on “Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections”
Karen D. Wright, Clinton F. Stewart